San Francisco, California, Sept 01, 2017:“Post-Myocardial Infarction Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017 – 2025” is a descriptive explanation of the drivers and restraints affecting this market, along with what readers of the report can do to make the most out of the opportunities in store over the coming years. Commonly known as heart attacks, a post-myocardial infarction is a very serious medical issue that holds heavy investments across the healthcare industry, in terms of research and development as well as treatments and preventive measures. The number of post-myocardial infarction cases are on the rise in the world due to various reasons, and the healthcare industry needs to pace up to successfully help treat as many patients as possible.
One of the key factors driving the global post-myocardial infarctions market currently, is the growing number of heart patients. Healthcare and medical studies are all showing the strong correlation between negative lifestyle choices and high chance of developing heart disease. Among the top issues driving heart disease rates are smoking and drinking, and leading a very hectic and stressful life. These factors are much more common among urban patients due to the increasingly work-oriented lives that people are leading.
According to a report published by the American Heart Association (AHA), as of 2014, one in three adults suffered from cardiac complications within the U.S. These conditions generally have a high likelihood of leading to myocardial infarction. Furthermore, AHA stated that over 350,000 new cases of heart failure were diagnosed among mail in the U.S. in 2013. Besides this, the Centers for Disease Control and Prevention found in 2009 that over 7 million Americans suffer acute heart attract. These are alarming statistics that are showing the need to put development of post-myocardial infarction treatments in high priority.
From a regional perspective, North America has consistently led the global post-myocardial infarctions market over the recent past, owing to the presence of a large number of advanced medical facilities, high awareness among patients, and a very high patient count for cardiovascular diseases. The region also shares a very high percentage of obese patients, who show very high chances of contractive cardiovascular diseases. Meanwhile, the demand for treatment options in post-myocardial infarctions are expected to surge in Asia Pacific over the coming years, owing to a swiftly evolving healthcare industry and high population densities in countries such as China and India.
The pharmaceutical and biotechnology companies currently exhibiting strong growth in the global post-myocardial infarction market are Merck, GlaxoSmithKline, Novartis, Sanofi, and Pfizer.
Click on the link below to request a sample copy of the report